Suppr超能文献

人类小细胞肺癌中I类组织相容性抗原、蛋白质和信使核糖核酸的表达显著降低。

Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.

作者信息

Doyle A, Martin W J, Funa K, Gazdar A, Carney D, Martin S E, Linnoila I, Cuttitta F, Mulshine J, Bunn P

出版信息

J Exp Med. 1985 May 1;161(5):1135-51. doi: 10.1084/jem.161.5.1135.

Abstract

We have found markedly deficient expression of the class I major histocompatibility antigens HLA-A,B,C and beta 2m on human small-cell lung cancer (SCLC) lines and fresh tumor samples. The deficit of HLA-A,B,C and beta 2-microglobulin (beta 2m) antigen expression was demonstrated with both radiobinding assays and indirect immunofluorescence assays. Immunoprecipitation of metabolically labeled cells with antibodies to class I antigens showed most SCLC lines to have synthesized almost no beta 2m and HLA-A,B,C proteins. Northern blot analysis, using human HLA-A,B, and beta 2m cDNA probes, showed that almost all SCLC lines tested had markedly decreased amounts of HLA and beta 2m mRNA, but both gene products could be induced with interferon treatment of SCLC lines. We conclude that human SCLC, in contrast to other lung cancer types, is characterized by greatly reduced transcription of HLA-A,B,C and beta 2m genes, which suggests the existence of a mechanism for evading the host immune response to the tumor and of an E1a-like product in this type of tumor cell.

摘要

我们发现,在人小细胞肺癌(SCLC)细胞系和新鲜肿瘤样本中,I类主要组织相容性抗原HLA - A、B、C以及β2微球蛋白(β2m)的表达明显不足。通过放射结合试验和间接免疫荧光试验均证实了HLA - A、B、C以及β2微球蛋白(β2m)抗原表达的缺陷。用针对I类抗原的抗体对代谢标记细胞进行免疫沉淀显示,大多数SCLC细胞系几乎没有合成β2m和HLA - A、B、C蛋白。使用人HLA - A、B和β2m cDNA探针进行的Northern印迹分析表明,几乎所有检测的SCLC细胞系中HLA和β2m mRNA的量都显著减少,但用干扰素处理SCLC细胞系可诱导这两种基因产物的产生。我们得出结论,与其他类型的肺癌相比,人SCLC的特征在于HLA - A、B、C和β2m基因的转录大幅减少,这表明存在一种逃避宿主对肿瘤免疫反应的机制,并且在这种类型的肿瘤细胞中存在一种类似E1a的产物。

相似文献

7
Interferon-mediated in vivo induction of beta 2-microglobulin on small-cell lung cancers and mid-gut carcinoids.
Clin Immunol Immunopathol. 1986 Oct;41(1):159-64. doi: 10.1016/0090-1229(86)90060-7.
9
Rescue of Daudi cell HLA expression by transfection of the mouse beta 2-microglobulin gene.
J Exp Med. 1988 Feb 1;167(2):288-99. doi: 10.1084/jem.167.2.288.

引用本文的文献

1
Characterization of the extrinsic and intrinsic signatures and therapeutic vulnerability of small cell lung cancers.
Signal Transduct Target Ther. 2025 Sep 10;10(1):290. doi: 10.1038/s41392-025-02378-6.
2
Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances.
J Exp Clin Cancer Res. 2025 Aug 23;44(1):251. doi: 10.1186/s13046-025-03503-7.
5
Current and future therapies for small cell lung carcinoma.
J Hematol Oncol. 2025 Apr 1;18(1):37. doi: 10.1186/s13045-025-01690-6.
6
Mechanisms of immunotherapy resistance in small cell lung cancer.
Cancer Drug Resist. 2024 Dec 28;7:55. doi: 10.20517/cdr.2024.154. eCollection 2024.
7
Advances in biomarkers for immunotherapy in small-cell lung cancer.
Front Immunol. 2024 Dec 11;15:1490590. doi: 10.3389/fimmu.2024.1490590. eCollection 2024.
10
Stimulation of cGAS-STING pathway as a challenge in the treatment of small cell lung cancer: a feasible strategy?
Br J Cancer. 2024 Nov;131(10):1567-1575. doi: 10.1038/s41416-024-02821-5. Epub 2024 Aug 31.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验